Literature DB >> 19023632

Use of positron emission tomography in surgery follow-up of esophageal cancer.

P Teyton1, J P Metges, A Atmani, V Jestin-Le Tallec, A Volant, D Visvikis, J P Bail, O Pradier, P Lozac'h, Catherine Cheze Le Rest.   

Abstract

INTRODUCTION: Although the prognosis of patients with esophageal cancer has been improved by extended dissection, the incidence of recurrence still remains high. In esophageal cancer, positron emission tomography (PET) using (18)F-fluorodeoxyglucose (FDG) already demonstrated to be useful for initial staging and monitoring response to therapy. This prospective study compared the ability of FDG-PET and conventional imaging to detect early recurrence of esophageal cancer after initial surgery in asymptomatic patients.
MATERIALS AND METHODS: Between October 2003 and September 2006, 41 patients with esophageal cancer were included in a prospective study after initial radical esophagectomy. FDG-PET, thoracoabdominal computed tomography (CT), abdominal ultrasonography, and endoscopy were performed every 6 months after initial treatment. RESULTS AND DISCUSSION: Twenty-three patients had recurrent disease (56%), mostly within the first 6 months after surgery (70%). Despite two false-positive scans due to postoperative changes, FDG-PET was more accurate than CT (91% vs. 81%, p = 0.02) for the detection of recurrence with a sensitivity of 100% (vs. 65%), a specificity of 85% (vs. 91%), and a negative predictive value of 100% on a patient-by-patient-based analysis. For the detection of locoregional recurrence, FDG-PET was more accurate than CT (96.2% vs. 88.9%). FDG-PET was also more accurate than CT for the detection of distant metastases (92.5% vs. 84.9%), especially when involving either bones (100%) or liver (98.1%). A lower sensitivity of FDG-PET (57%) for the early detection of small lung metastases did not affect patient management (accuracy = 92.5%).
CONCLUSION: FDG-PET appears to be very useful for the systematic follow-up of asymptomatic patients after esophagectomy with an initial scan performed 6 months after surgery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19023632     DOI: 10.1007/s11605-008-0749-7

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  39 in total

1.  Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.

Authors:  Dirk Hellwig; Andreas Gröschel; Thomas P Graeter; Anne P Hellwig; Ursula Nestle; Hans-Joachim Schäfers; Gerhard W Sybrecht; Carl-Martin Kirsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-09       Impact factor: 9.236

2.  The role of salvage surgery for recurrence of esophageal squamous cell cancer.

Authors:  S Natsugoe; H Okumura; M Matsumoto; Y Uchikado; T Setoyama; Y Uenosono; S Ishigami; T Owaki; T Aikou
Journal:  Eur J Surg Oncol       Date:  2006-03-29       Impact factor: 4.424

3.  Survival and clinical evaluation of salvage operation for cervical lymph node recurrence in esophageal cancer.

Authors:  Shuhei Komatsu; Yasuhiro Shioaki; Daisuke Ichikawa; Takashi Hamashima; Keitaro Kan; Yasuo Ueshima; Kazuma Koide; Chol Joo Lee; Eito Ikeda; Fumitaka Mutoh; Hideaki Kurioka; Takahiro Oka; Hisakazu Yamagishi
Journal:  Hepatogastroenterology       Date:  2005 May-Jun

Review 4.  Chemoradiation in the management of esophageal cancer.

Authors:  Lawrence Kleinberg; Arlene A Forastiere
Journal:  J Clin Oncol       Date:  2007-09-10       Impact factor: 44.544

5.  Metachronous cancer of gastroplasty after esophagectomy.

Authors:  A Atmani; P Topart; F Vandenbroucke; A Louzi; L Ferrand; P Lozac'h
Journal:  Dis Esophagus       Date:  2006       Impact factor: 3.429

6.  Likelihood ratios. Another enhancement of sensitivity and specificity.

Authors:  J R Beck
Journal:  Arch Pathol Lab Med       Date:  1986-08       Impact factor: 5.534

7.  Combined radiochemotherapy for postoperative recurrence of oesophageal cancer.

Authors:  J L Raoul; E Le Prisé; B Meunier; V Julienne; P L Etienne; M Gosselin; B Launois
Journal:  Gut       Date:  1995-08       Impact factor: 23.059

8.  Localization of recurrent disease after extended lymph node dissection for carcinoma of the thoracic esophagus.

Authors:  T Matsubara; M Ueda; T Takahashi; T Nakajima; M Nishi
Journal:  J Am Coll Surg       Date:  1996-04       Impact factor: 6.113

9.  Prognostic value of initial fluorodeoxyglucose-PET in esophageal cancer: a prospective study.

Authors:  Catherine Cheze-Le Rest; Jean-Philippe Metges; Pierre Teyton; Véronique Jestin-Le Tallec; P Lozac'h; A Volant; D Visvikis
Journal:  Nucl Med Commun       Date:  2008-07       Impact factor: 1.690

10.  Imaging characteristics of a 3-dimensional GSO whole-body PET camera.

Authors:  Suleman Surti; Joel S Karp
Journal:  J Nucl Med       Date:  2004-06       Impact factor: 10.057

View more
  9 in total

1.  Diagnostic value of surveillance 18F-fluorodeoxyglucose PET/CT for detecting recurrent esophageal carcinoma after curative treatment.

Authors:  Soo Jeong Kim; Seung Hyup Hyun; Seung Hwan Moon; Kyung Soo Lee; Jong-Mu Sun; Dongryul Oh; Yong Chan Ahn; Jae Il Zo; Young Mog Shim; Joon Young Choi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-06-20       Impact factor: 9.236

Review 2.  The role of ¹⁸F-FDG PET imaging in upper gastrointestinal malignancies.

Authors:  Tong Dai; Elizabeta Popa; Manish A Shah
Journal:  Curr Treat Options Oncol       Date:  2014-09

3.  18FDG-PET/CT is useful in the follow-up of surgically treated patients with oesophageal adenocarcinoma.

Authors:  Sonia L Betancourt Cuellar; Diana P Palacio; Carol C Wu; Brett W Carter; Arlene M Correa; Wayne L Hofstetter; Edith M Marom
Journal:  Br J Radiol       Date:  2017-11-28       Impact factor: 3.039

Review 4.  Role of ¹⁸F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies.

Authors:  Elizabeth C Smyth; Manish A Shah
Journal:  World J Gastroenterol       Date:  2011-12-14       Impact factor: 5.742

5.  Diagnostic accuracy of ¹⁸F-FDG PET/CT for detection of suspected recurrence in patients with oesophageal carcinoma.

Authors:  Punit Sharma; Sachin Jain; Sellam Karunanithi; Sujoy Pal; Pramod Kumar Julka; Sanjay Thulkar; Arun Malhotra; Chandrasekhar Bal; Rakesh Kumar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-17       Impact factor: 9.236

Review 6.  The value of [18F]fluorodeoxyglucose-PET/CT in oesophageal cancer.

Authors:  S Rankin
Journal:  Cancer Imaging       Date:  2011-10-03       Impact factor: 3.909

7.  The usefulness of standardized uptake value in differentiation between benign and malignant thyroid lesions detected incidentally in 18F-FDG PET/CT examination.

Authors:  Adam Stangierski; Kosma Woliński; Rafał Czepczyński; Agata Czarnywojtek; Martha Lodyga; Anna Wyszomirska; Małgorzata Janicka-Jedyńska; Maciej Bączyk; Marek Ruchała
Journal:  PLoS One       Date:  2014-10-08       Impact factor: 3.240

8.  18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer.

Authors:  Ronald L Korn; Daniel D Von Hoff; Mitesh J Borad; Markus F Renschler; Desmond McGovern; R Curtis Bay; Ramesh K Ramanathan
Journal:  Cancer Imaging       Date:  2017-08-03       Impact factor: 3.909

9.  Value of regular endosonography and [18F]fluorodeoxyglucose PET-CT after surgery for gastro-oesophageal junction, stomach or pancreatic cancer.

Authors:  O S Bjerring; S Hess; H Petersen; C W Fristrup; L Lundell; M B Mortensen
Journal:  BJS Open       Date:  2021-03-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.